Octreotide 50 mcg and 100 mcg per ml ampoules: Supply issue

Supply issue Active

The octreotide 50 mcg/ml (Pharmacode 2629534) is temporarily out of stock and the low stock availability for the 100 mcg/ml (Pharmacode 2629518).

Reason for the issue

The supplier for octreotide injection (Max Health) has advised that due to manufacturing issues caused by the global shortage of CO2 there is a supply issue affecting the 50 mcg/ml and 100 mcg/ml presentations of octreotide. 

Affected product

Max Health is temporarily out of stock of the 50 mcg/ml (Pharmacode 2629534).

There is enough stock of the 100 mcg/ml (Pharmacode 2629518) stock in the suply chain to last to mid/late February, at standard usage rates. 

There is ample stock of the 500 mcg/ml presentation (Pharmacode 2629526)

Schedule listing for octreotide(external link)

Alternative products

50 mcg/ml 

An alternative brand for the 50mcg per ml presentation is listed on the Schedule. Max Health has confirmed this is in the country and available for purchase. This product is not Medsafe approved so must be prescribed and dispensed in line with section 29 of the Medicines Act.

Octreotide inj 50mcg (listed and available for Community and Hospital)

  • Chemical: Octreotide
  • Presentation: Inj 50 mcg per ml, 1 ml ampoule
  • Brand: Octreotide GH
  • Pack size: 5
  • Subsidy and price: $27.58
  • Pharmacode: 2595907

Section 29 and wastage rules apply. 

100 mcg/ml 

Max Health also has the 100mcg alternative in the country, however this is not currently listed. Pharmac has requested that Max Health allocate remaining stock of their funded brand to community pharmacies, as hospitals are able to purchase the alternative brand before it is listed in the Schedule.

Pharmac will list this alternative as soon as possible.  

Octreotide inj 100mcg (Available for Hospital only)

  • Chemical: Octreotide
  • Presentation: Inj 100 mcg per ml, 1 ml ampoule
  • Brand: Octreotide GH
  • Pack size: 5
  • Subsidy and price: $32.71
  • Pharmacode: 2595885

Prescribing and supplying a medicine under section 29

Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – e.g., doctors. 

We know supplying a medicine under section 29 is not ideal. This is the only alternative available to ensure people can continue to access treatment. 

We apologise for any inconvenience this causes. 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website(external link)

What patients need to know about section 29 medicines – Health Navigator website(external link)


Max Health have advised that they are expecting a shipment to arrive at the end of March 2023.

Who to contact

If you have any queries regarding this supply issue, contact Max Health on 09 815 2664.